{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:37:16Z","timestamp":1776868636684,"version":"3.51.2"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jneuroim.2020.577144","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T02:48:18Z","timestamp":1578365298000},"page":"577144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Refractory epilepsy associated with anti-ribosomal P antibodies successfully treated with topiramate"],"prefix":"10.1016","volume":"340","author":[{"given":"R.","family":"Uribe-San-Mart\u00edn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ciampi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.P.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"V\u00e1squez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"C\u00e1rcamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jneuroim.2020.577144_bb0005","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.jneuroim.2020.577144_bb0010","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM198707303170503","article-title":"Association between lupus psychosis and anti-ribosomal P protein antibodies","volume":"317","author":"Bonfa","year":"1987","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jneuroim.2020.577144_bb0015","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1097\/MJT.0b013e3182491c31","article-title":"Lamotrigine-induced lupus-like syndrome: a case report and literature review","volume":"21","author":"Chang","year":"2014","journal-title":"Am. J. Ther."},{"issue":"19","key":"10.1016\/j.jneuroim.2020.577144_bb0020","doi-asserted-by":"crossref","first-page":"7419","DOI":"10.1073\/pnas.83.19.7419","article-title":"Identification and chemical synthesis of a ribosomal protein antigenic determinant in systemic lupus erythematosus","volume":"83","author":"Elkon","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.jneuroim.2020.577144_bb0025","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jneuroim.2020.577144_bb0030","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1177\/0961203316666185","article-title":"Electrophysiological dysfunction induced by anti-ribosomal P protein antibodies injection into the lateral ventricle of the rat brain","volume":"26","author":"Gaburo","year":"2017","journal-title":"Lupus."},{"key":"10.1016\/j.jneuroim.2020.577144_bb0035","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.autrev.2015.10.003","article-title":"A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus","volume":"15","author":"Ho","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jneuroim.2020.577144_bb0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2019.2384","article-title":"Tackling epilepsy with high-definition precision medicine: a review","author":"Kearney","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2020.577144_bb0045","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia."},{"issue":"6","key":"10.1016\/j.jneuroim.2020.577144_bb0050","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/art.39081","article-title":"Pathogenicity of lupus anti-ribosomal P antibodies: role of cross-reacting neuronal surface P antigen in glutamatergic transmission and plasticity in a mouse model","volume":"67","author":"Segovia-Miranda","year":"2015","journal-title":"Arthritis Rheum."},{"issue":"Suppl. 1","key":"10.1016\/j.jneuroim.2020.577144_bb0055","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1111\/j.1528-1157.2000.tb02163.x","article-title":"An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action","volume":"41","author":"Shank","year":"2000","journal-title":"Epilepsia."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572819305338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572819305338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:34:44Z","timestamp":1759048484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572819305338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":11,"alternative-id":["S0165572819305338"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577144","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Refractory epilepsy associated with anti-ribosomal P antibodies successfully treated with topiramate","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"577144"}}